Caffeine promotes endothelial progenitor cell survival in SLE
Caffeine may protect against endothelial dysfunction in patients with systemic lupus erythematosus, suggest Italian researchers.
First-line trabectedin use boosts OS for advanced leiomyosarcoma
LMS-04 trial findings show a significant overall survival benefit with the use of induction and maintenance trabectedin alongside first-line doxorubicin for patients with inoperable, advanced leiomyosarcoma.
Maralixibat improves itch, bile acid concentrations in paediatric PFIC
Treatment with the ileal bile acid transporter inhibitor maralixibat relieves morning itch for children with different types of progressive familial intrahepatic cholestasis, show phase 3 study findings published in The Lancet Gastroenterology and Hepatology.
EV-302 results ‘a leap forward’ for advanced urothelial carcinoma
Phase 3 trial findings demonstrate a significant improvement in overall survival for patients with treatment-naïve, advanced urothelial carcinoma who receive a combination of enfortumab vedotin and pembrolizumab compared with chemotherapy.
Home insulin pump use feasible for hospitalised children with type 1 diabetes
For children with type 1 diabetes who are admitted to hospital, continuing with a home insulin pump is feasible for the prevention of hyperglycemia and hypoglycemia, suggests research published in JAMA Network Open.
Autoimmune disease risk increased after surgical remission of Cushing’s disease
Patients with Cushing’s disease who achieve remission following surgery have an increased incidence of autoimmune disease, suggest findings published in the Annals of Internal Medicine in February 2024.
Mycophenolate mofetil withdrawal feasible in SLE patients with stable disease
Patients with systemic lupus erythematosus may be able to stop taking mycophenolate mofetil once their condition becomes stable without significantly increasing their risk for flare compared with continuing treatment, suggests an open-label, randomized controlled trial.
This independent news story was supported by an educational grant from L’Institut Servier, Suresnes, France.
Tixagevimab plus cilgavimab offers COVID-19 protection for haematological cancer patients
Tixagevimab and cilgavimab immunoprophylaxis may help protect patients with haematological malignancies from COVID-19 infection and hospitalisation, suggests a research letter published in JAMA Oncology.
This independent news story was supported by an educational grant from L’Institut Servier, Suresnes, France.
Blood immunoassay shows high diagnostic accuracy for Alzheimer’s disease pathology
A commercially available plasma phosphorylated (p)-tau217 immunoassay outperforms other biomarkers in accurately identifying biological Alzheimer’s disease, suggest findings from a study across three observational cohorts.
This independent news story was supported by an educational grant from L’Institut Servier, Suresnes, France.
Bevacizumab addition to temozolomide chemotherapy may improve neuroblastoma response
Findings from the BEACON-Neuroblastoma trial suggest that adding bevacizumab to temozolomide-based chemotherapy may improve the objective response rate for children with high-risk, relapsed or refractory disease.
This independent news story was supported by an educational grant from L’Institut Servier, Suresnes, France.
